Brief: Theravance Biopharma Announces Orphan Drug Designation Granted To Ampreloxetine
09/05/2023 23:18
May 9 (Reuters) - Theravance Biopharma Inc TBPH.O :
* THERAVANCE BIOPHARMA, INC. ANNOUNCES ORPHAN DRUG
DESIGNATION
GRANTED TO AMPRELOXETINE FOR THE TREATMENT OF SYMPTOMATIC
NEUROGENIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH MULTIPLE
SYSTEM ATROPHY
Source text for Eikon: ID:nPn5s9YCDa
Further company coverage: TBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy